We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer and Cellectis Enter Cancer Fighting Collaboration

Pfizer and Cellectis Enter Cancer Fighting Collaboration

June 18, 2014

Pfizer announced Wednesday it had signed a deal with French biotech company Cellectis to develop Chimeric Antigen Receptor T-cell (CAR-T), immunotherapy drugs for the treatment of cancer.

According to the deal, Pfizer will pay Cellectis an upfront payment of $80 million, as well as providing funding for research costs. The French firm also will be eligible to receive development, regulatory and commercial milestone payments of up to $185 million per Pfizer product, plus tiered royalties on any future sales.

Pfizer will also obtain a 10 percent stake in Cellectis through newly issued shares, purchased at $12.55 a piece, the company said.

CAR-T immunotherapies use engineered and reprogrammed immune system cells from a single donor for use in multiple patients. This approach differs from other autologous technologies that rely on engineering a patient's own T-cells. The goal of CAR-T therapy is to eventually treat cancer using a standardized, off-the-shelf therapeutic product to hunt out cancer, Cellectis said.

Pfizer has exclusive rights to develop products against 15 biological targets for fighting cancer it selects, while another 12 targets can be selected by Cellectis — who will also oversee clinical development and commercialization of CAR-T therapeutics. Cellectis said it expects to open a site in the U.S. to work more closely with Pfizer.

The French drugmaker's research is still at an early stage but it hopes to start clinical trials in 2015, initially with a leukemia drug, it said. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing